The U.S. Food and Drug Administration has approved AstraZeneca and partner Daiichi Sankyo's precision drug to treat a type of ...
AstraZeneca has overhauled its local management in China, replacing Michael Lai with Alex Lin as the country's general ...
A high-dose form of Novo’s obesity drug led to 20% weight loss over 72 weeks. Meanwhile, Atara got a complete response letter ...
Analysts predict sales of Dato-DXd could hit $5.9 billion in 2030, but the antibody-drug conjugate faced a series of setbacks ...
The approval of Calquence marks the first and only BTK inhibitor approved for the first-line treatment of MCL in the US.
Shares of AstraZeneca PLC AZN slid 1.32% to £107.94 Monday, on what proved to be an all-around great trading session for the ...
SYDNEY, Jan. 21, 2025 /PRNewswire/ -- Trinasolar, a global leader in smart PV and energy storage, has partnered with Smart ...
Sachin Jain, an analyst from Bank of America Securities, reiterated the Buy rating on AstraZeneca (AZN – Research Report). The associated price ...
AstraZeneca’s respiratory and immunology portfolio is driving significant growth, with R&I assets forecasted to account for ...
A drug from AstraZeneca and Daiichi Sankyo won authorization for a form of breast cancer, the first U.S. approval for the ...
New Treatments for HR-Positive Breast Cancer and Mantle Cell Lymphoma Offer Promising Outcomes and Expanded Options for ...
AstraZeneca AZN announced that the FDA has approved its antibody-drug conjugate (ADC), datopotamab deruxtecan (or Dato-DXd), ...